4//SEC Filing
Myer Vickesh 4
Accession 0001179110-18-014142
CIK 0001650664other
Filed
Dec 18, 7:00 PM ET
Accepted
Dec 19, 4:41 PM ET
Size
16.3 KB
Accession
0001179110-18-014142
Insider Transaction Report
Form 4
Myer Vickesh
Chief Technology Officer
Transactions
- Sale
Common Stock
2018-12-17$27.75/sh−2,300$63,825→ 700 total - Exercise/Conversion
Common Stock
2018-12-18$11.21/sh+4,000$44,840→ 4,000 total - Sale
Common Stock
2018-12-18$27.41/sh−4,000$109,640→ 0 total - Exercise/Conversion
Stock Option (right to buy)
2018-12-17−3,000→ 82,307 totalExercise: $0.65Exp: 2025-04-29→ Common Stock (3,000 underlying) - Exercise/Conversion
Stock Option (right to buy)
2018-12-18−4,000→ 56,897 totalExercise: $11.21Exp: 2025-10-29→ Common Stock (4,000 underlying) - Sale
Common Stock
2018-12-17$28.34/sh−700$19,838→ 0 total - Exercise/Conversion
Common Stock
2018-12-17$0.65/sh+3,000$1,950→ 3,000 total
Footnotes (6)
- [F1]The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017.
- [F2]This transaction was executed in multiple trades at prices ranging from $27.22 to $28.20. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and the prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $28.22 to $28.53. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and the prices at which the transaction was effected.
- [F4]This transaction was executed in multiple trades at prices ranging from $27.16 to $27.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and the prices at which the transaction was effected.
- [F5]This option was granted on April 30, 2015 and is scheduled to vest over four years, with 25% of the shares having vested on April 21, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through April 21, 2019.
- [F6]This option was granted on October 30, 2015 and is scheduled to vest over four years, with 25% of the shares having vested on October 27, 2016 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through October 27, 2019.
Documents
Issuer
Editas Medicine, Inc.
CIK 0001650664
Entity typeother
Related Parties
1- filerCIK 0001742806
Filing Metadata
- Form type
- 4
- Filed
- Dec 18, 7:00 PM ET
- Accepted
- Dec 19, 4:41 PM ET
- Size
- 16.3 KB